EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

Heike Schönherr iD, Pelin Ayaz iD, Alexander M Taylor, Jessica B Casaletto, B Barry Touré iD, Demetri T Moustakas, Brandi M Hudson iD, Roberto Valverde iD, Songping Zhao iD, Patrick J O'Hearn, Lindsey Foster iD, Dina A Sharon iD und 17 weitere

Proceedings of the National Academy of Sciences · 06.02.2024 · 121 (6)

DOI: 10.1073/pnas.2317756121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024-02. Verfasst von Heike Schönherr und 28 weiteren Autor:innen. Beteiligte Einrichtung: Relay Therapeutics, Cambridge, MA 02139. Hauptthemen laut MEDLINE: Hyperphosphatemia, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Relay Therapeutics (Relay), D. E. Shaw Research, Pharmaron.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factor receptor (FGFR) kinase inhibitors have been shown to be effective in the treatment of intrahepatic cholangiocarcinoma and other advanced solid tumors harboring FGFR2 alterations, but the toxicity of these drugs frequently leads to dose reduction or interruption of treatment such that maximum efficacy cannot be achieved. The most common adverse effects are hyperphosphatemia caused by FGFR1 inhibition and diarrhea due to FGFR4 inhibition, as current therapies are not selective among the FGFRs. Designing selective inhibitors has proved difficult with conventional approaches because the orthosteric sites of FGFR family members are observed to be highly similar in X-ray structures. In this study, aided by analysis of protein dynamics, we designed a selective, covalent FGFR2 inhibitor. In a key initial step, analysis of long-timescale molecular dynamics simulations of the FGFR1 and FGFR2 kinase domains allowed us to identify differential motion in their P-loops, which are located adjacent to the orthosteric site. Using this insight, we were able to design orthosteric binders that selectively and covalently engage the P-loop of FGFR2. Our drug discovery efforts culminated in the development of lirafugratinib (RLY-4008), a covalent inhibitor of FGFR2 that shows substantial selectivity over FGFR1 (~250-fold) and FGFR4 (~5,000-fold) in vitro, causes tumor regression in multiple FGFR2 -altered human xenograft models, and was recently demonstrated to be efficacious in the clinic at doses that do not induce clinically significant hyperphosphatemia or diarrhea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperphosphatemiaCholangiocarcinomaBile Duct NeoplasmsHumansReceptor, Fibroblast Growth Factor, Type 2Bile Ducts, IntrahepaticDiarrheaProtein Kinase Inhibitors

Stichwörter der Autor:innen

FGFR2 inhibitorcholangiocarcinomamolecular dynamics simulationmotion-based drug design

Substanzen

Receptor, Fibroblast Growth Factor, Type 2Protein Kinase InhibitorsFGFR2 protein, human

Autor:innen und Institutionen

  • Relay Therapeutics, Cambridge, MA 02139.
  • D. E. Shaw Research, New York, NY 10036.
  • Pharmaron Beijing Co., Ltd., Beijing 100176, People's Republic of China.
  • Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032.

ORCID-Profile: Heike Schönherr, Pelin Ayaz, B Barry Touré, Brandi M Hudson, Roberto Valverde, Songping Zhao, Lindsey Foster, Dina A Sharon, Thomas H McLean, David E Shaw

Förderung

  • Relay Therapeutics (Relay)
  • D. E. Shaw Research
  • Pharmaron

Zitieren

APA

Schönherr, H., Ayaz, P., Taylor, A. M., Casaletto, J. B., Touré, B. B., Moustakas, D. T., Hudson, B. M., Valverde, R., Zhao, S., O'Hearn, P. J., Foster, L., Sharon, D. A., Garfinkle, S., Giordanetto, F., Lescarbeau, A., Kurukulasuriya, R., Gerami-Moayed, N., Maglic, D., Bruderek, K., …, & Bergstrom, D. A. (2024). Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences, 121(6). https://doi.org/10.1073/pnas.2317756121

Vancouver

Schönherr H, Ayaz P, Taylor AM, Casaletto JB, Touré BB, Moustakas DT, et al. Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences. 2024;121(6). doi:10.1073/pnas.2317756121

BibTeX
@article{Schnherr2024,
  author = {Schönherr, Heike and Ayaz, Pelin and Taylor, Alexander M and Casaletto, Jessica B and Touré, B Barry and Moustakas, Demetri T and Hudson, Brandi M and Valverde, Roberto and Zhao, Songping and O'Hearn, Patrick J and Foster, Lindsey and Sharon, Dina A and Garfinkle, Sam and Giordanetto, Fabrizio and Lescarbeau, André and Kurukulasuriya, Ravi and Gerami-Moayed, Nastaran and Maglic, Dejan and Bruderek, Kamil and Naik, Gaauri and Gunaydin, Hakan and Mader, Mary M and Boezio, Alessandro A and McLean, Thomas H and Chen, Rongfeng and Wang, Yanxia and Shaw, David E and Watters, James and Bergstrom, Donald A},
  title = {Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {6},
  doi = {10.1073/pnas.2317756121}
}
Kostenlos starten →